Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse

M. Tampellini, A. Berruti, G. Gorzegno, R. Bitossi, A. Bottini, A. Durando, A. De Matteis, A. Farris, M. Donadio, E. De Fabiani, E. Manzin, P. Arese, M. G. Sarobba, F. Castiglione, G. Moro, G. Bonazzi, F. Nuzzo, M. Massobrio, Luigi Dogliotti

Research output: Contribution to journalArticle

Abstract

Data currently available are insufficient to demonstrate a real utility for CA 15-3 in the diagnosis, staging or surveillance of breast cancer patients following primary treatment. The aim of this study was to determine if there was a correlation between supranormal CA 15-3 serum levels and clinical and biological variables in breast cancer patients at first disease relapse. From October 1988 to March 1998, 430 consecutive patients entered the study. Overall CA 15-3 sensitivity was 60.7%. Elevated CA 15-3 levels were found more frequently in patients with liver metastases (74.6%) and in those with pleural effusion (75.7%). CA 15-3 sensitivity was 70.4% in patients with estrogen-receptor-positive (ER+) primary tumors and 45.9% in those with estrogen-receptor-negative (ER-) tumors (p <0.0001). In patients with a limited extent of disease, marker sensitivity was 57.7% in ER+ tumors and 25.7% in ER- tumors (p <0.0001). Logistic regression analysis showed ER status, disease extent and pleural effusion as independent variables associated with CA 15-3 positivity. The multivariate Cox analysis showed ER and disease extent as independent variables predicting overall survival, whereas CA 15-3 failed to be statistically significant. CA 15-3 was an independent variable only when the disease extent variable was removed. This study suggests that CA 15-3 in advanced breast cancer patients is a marker of both disease extent and ER status. The direct relationship with ER status indicates that CA 15-3 diagnostic sensitivity in the early detection of disease recurrence could be greater in ER+ patients than in ER- ones. Furthermore, this suggests that patients with elevated CA 15-3 levels could have disease that is more sensitive to hormone manipulation than those with normal CA 15-3 values.

Original languageEnglish
Pages (from-to)367-373
Number of pages7
JournalTumor Biology
Volume22
Issue number6
DOIs
Publication statusPublished - 2001

Fingerprint

Breast Neoplasms
Recurrence
Serum
Estrogen Receptors
Pleural Effusion
Neoplasms
Early Diagnosis
Multivariate Analysis
Logistic Models
Regression Analysis
Hormones
Neoplasm Metastasis
Survival
Liver

Keywords

  • Disease extent
  • Estrogen receptor
  • Prognostic factors

ASJC Scopus subject areas

  • Cancer Research

Cite this

Tampellini, M., Berruti, A., Gorzegno, G., Bitossi, R., Bottini, A., Durando, A., ... Dogliotti, L. (2001). Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. Tumor Biology, 22(6), 367-373. https://doi.org/10.1159/000050639

Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. / Tampellini, M.; Berruti, A.; Gorzegno, G.; Bitossi, R.; Bottini, A.; Durando, A.; De Matteis, A.; Farris, A.; Donadio, M.; De Fabiani, E.; Manzin, E.; Arese, P.; Sarobba, M. G.; Castiglione, F.; Moro, G.; Bonazzi, G.; Nuzzo, F.; Massobrio, M.; Dogliotti, Luigi.

In: Tumor Biology, Vol. 22, No. 6, 2001, p. 367-373.

Research output: Contribution to journalArticle

Tampellini, M, Berruti, A, Gorzegno, G, Bitossi, R, Bottini, A, Durando, A, De Matteis, A, Farris, A, Donadio, M, De Fabiani, E, Manzin, E, Arese, P, Sarobba, MG, Castiglione, F, Moro, G, Bonazzi, G, Nuzzo, F, Massobrio, M & Dogliotti, L 2001, 'Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse', Tumor Biology, vol. 22, no. 6, pp. 367-373. https://doi.org/10.1159/000050639
Tampellini, M. ; Berruti, A. ; Gorzegno, G. ; Bitossi, R. ; Bottini, A. ; Durando, A. ; De Matteis, A. ; Farris, A. ; Donadio, M. ; De Fabiani, E. ; Manzin, E. ; Arese, P. ; Sarobba, M. G. ; Castiglione, F. ; Moro, G. ; Bonazzi, G. ; Nuzzo, F. ; Massobrio, M. ; Dogliotti, Luigi. / Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. In: Tumor Biology. 2001 ; Vol. 22, No. 6. pp. 367-373.
@article{f0b17742c04d4926a04d001892d7aa8e,
title = "Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse",
abstract = "Data currently available are insufficient to demonstrate a real utility for CA 15-3 in the diagnosis, staging or surveillance of breast cancer patients following primary treatment. The aim of this study was to determine if there was a correlation between supranormal CA 15-3 serum levels and clinical and biological variables in breast cancer patients at first disease relapse. From October 1988 to March 1998, 430 consecutive patients entered the study. Overall CA 15-3 sensitivity was 60.7{\%}. Elevated CA 15-3 levels were found more frequently in patients with liver metastases (74.6{\%}) and in those with pleural effusion (75.7{\%}). CA 15-3 sensitivity was 70.4{\%} in patients with estrogen-receptor-positive (ER+) primary tumors and 45.9{\%} in those with estrogen-receptor-negative (ER-) tumors (p <0.0001). In patients with a limited extent of disease, marker sensitivity was 57.7{\%} in ER+ tumors and 25.7{\%} in ER- tumors (p <0.0001). Logistic regression analysis showed ER status, disease extent and pleural effusion as independent variables associated with CA 15-3 positivity. The multivariate Cox analysis showed ER and disease extent as independent variables predicting overall survival, whereas CA 15-3 failed to be statistically significant. CA 15-3 was an independent variable only when the disease extent variable was removed. This study suggests that CA 15-3 in advanced breast cancer patients is a marker of both disease extent and ER status. The direct relationship with ER status indicates that CA 15-3 diagnostic sensitivity in the early detection of disease recurrence could be greater in ER+ patients than in ER- ones. Furthermore, this suggests that patients with elevated CA 15-3 levels could have disease that is more sensitive to hormone manipulation than those with normal CA 15-3 values.",
keywords = "Disease extent, Estrogen receptor, Prognostic factors",
author = "M. Tampellini and A. Berruti and G. Gorzegno and R. Bitossi and A. Bottini and A. Durando and {De Matteis}, A. and A. Farris and M. Donadio and {De Fabiani}, E. and E. Manzin and P. Arese and Sarobba, {M. G.} and F. Castiglione and G. Moro and G. Bonazzi and F. Nuzzo and M. Massobrio and Luigi Dogliotti",
year = "2001",
doi = "10.1159/000050639",
language = "English",
volume = "22",
pages = "367--373",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "6",

}

TY - JOUR

T1 - Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse

AU - Tampellini, M.

AU - Berruti, A.

AU - Gorzegno, G.

AU - Bitossi, R.

AU - Bottini, A.

AU - Durando, A.

AU - De Matteis, A.

AU - Farris, A.

AU - Donadio, M.

AU - De Fabiani, E.

AU - Manzin, E.

AU - Arese, P.

AU - Sarobba, M. G.

AU - Castiglione, F.

AU - Moro, G.

AU - Bonazzi, G.

AU - Nuzzo, F.

AU - Massobrio, M.

AU - Dogliotti, Luigi

PY - 2001

Y1 - 2001

N2 - Data currently available are insufficient to demonstrate a real utility for CA 15-3 in the diagnosis, staging or surveillance of breast cancer patients following primary treatment. The aim of this study was to determine if there was a correlation between supranormal CA 15-3 serum levels and clinical and biological variables in breast cancer patients at first disease relapse. From October 1988 to March 1998, 430 consecutive patients entered the study. Overall CA 15-3 sensitivity was 60.7%. Elevated CA 15-3 levels were found more frequently in patients with liver metastases (74.6%) and in those with pleural effusion (75.7%). CA 15-3 sensitivity was 70.4% in patients with estrogen-receptor-positive (ER+) primary tumors and 45.9% in those with estrogen-receptor-negative (ER-) tumors (p <0.0001). In patients with a limited extent of disease, marker sensitivity was 57.7% in ER+ tumors and 25.7% in ER- tumors (p <0.0001). Logistic regression analysis showed ER status, disease extent and pleural effusion as independent variables associated with CA 15-3 positivity. The multivariate Cox analysis showed ER and disease extent as independent variables predicting overall survival, whereas CA 15-3 failed to be statistically significant. CA 15-3 was an independent variable only when the disease extent variable was removed. This study suggests that CA 15-3 in advanced breast cancer patients is a marker of both disease extent and ER status. The direct relationship with ER status indicates that CA 15-3 diagnostic sensitivity in the early detection of disease recurrence could be greater in ER+ patients than in ER- ones. Furthermore, this suggests that patients with elevated CA 15-3 levels could have disease that is more sensitive to hormone manipulation than those with normal CA 15-3 values.

AB - Data currently available are insufficient to demonstrate a real utility for CA 15-3 in the diagnosis, staging or surveillance of breast cancer patients following primary treatment. The aim of this study was to determine if there was a correlation between supranormal CA 15-3 serum levels and clinical and biological variables in breast cancer patients at first disease relapse. From October 1988 to March 1998, 430 consecutive patients entered the study. Overall CA 15-3 sensitivity was 60.7%. Elevated CA 15-3 levels were found more frequently in patients with liver metastases (74.6%) and in those with pleural effusion (75.7%). CA 15-3 sensitivity was 70.4% in patients with estrogen-receptor-positive (ER+) primary tumors and 45.9% in those with estrogen-receptor-negative (ER-) tumors (p <0.0001). In patients with a limited extent of disease, marker sensitivity was 57.7% in ER+ tumors and 25.7% in ER- tumors (p <0.0001). Logistic regression analysis showed ER status, disease extent and pleural effusion as independent variables associated with CA 15-3 positivity. The multivariate Cox analysis showed ER and disease extent as independent variables predicting overall survival, whereas CA 15-3 failed to be statistically significant. CA 15-3 was an independent variable only when the disease extent variable was removed. This study suggests that CA 15-3 in advanced breast cancer patients is a marker of both disease extent and ER status. The direct relationship with ER status indicates that CA 15-3 diagnostic sensitivity in the early detection of disease recurrence could be greater in ER+ patients than in ER- ones. Furthermore, this suggests that patients with elevated CA 15-3 levels could have disease that is more sensitive to hormone manipulation than those with normal CA 15-3 values.

KW - Disease extent

KW - Estrogen receptor

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=18244388200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244388200&partnerID=8YFLogxK

U2 - 10.1159/000050639

DO - 10.1159/000050639

M3 - Article

C2 - 11786730

AN - SCOPUS:18244388200

VL - 22

SP - 367

EP - 373

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 6

ER -